Disease · MONDO_0002154

trichomoniasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. trichomoniasis. Diseases, record MONDO_0002154. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002154

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: trichomoniasis; Open Targets
Open Targets ID: MONDO_0002154; Open Targets
Other names: Trichomonas Infections, Trichomonas infection; Open Targets
Disease Ontology: DOID:1947; Disease Ontology
MeSH: D014245; MeSH
NCI Thesaurus: C35720; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 7 drugs, from DailyMed; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METRONIDAZOLE	CHEMBL137	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
SECNIDAZOLE	CHEMBL498847	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
TINIDAZOLE	CHEMBL1220	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MICONAZOLE	CHEMBL91	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PRAZIQUANTEL	CHEMBL976	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00322465	NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)	Phase 2	305	2011-08-17	Urethritis	AZITHROMYCIN, DOXYCYCLINE, TINIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01018095	Trichomonas Vaginalis Recurrence Among HIV+ Women	Phase 4	270	2013-07-15	Trichomonas Infections, HIV Infections	METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03935217	A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis	Phase 3	147	2023-10-04	Trichomonas Infection	SECNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01361048	Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis	Phase 2	40	2014-02-20	Trichomonas Vaginitis	METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01335373	Observational Program Neo-Penotran® Forte		13,024		Vaginal Candidiasis, Bacterial Vaginosis, Trichomonal Vaginitis	METRONIDAZOLE, MICONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06261840	Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole	Phase 4	1,200		Trichomonas Vaginitis, Bacterial Vaginitis	METRONIDAZOLE, SECNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00713999	Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar	Not applicable	680		Sexually Transmitted Infections, Schistosoma Haematobium	PRAZIQUANTEL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
7 Day Dose vs Single Dose: serious adverse events	0 of 135	0 of 135	270	NCT01018095	Trial comparisons
7 Day Dose vs Single Dose: TV Culture Positive Result	11 of 130	21 of 125	255	NCT01018095	Trial comparisons
7 Day Dose vs Single Dose: TV Culture Positive Result	8 of 73	19 of 79	152	NCT01018095	Trial comparisons
Solosec (Containing 2 Grams of Secnidazole) vs Placebo: deaths from any cause	0 of 74	0 of 73	147	NCT03935217	Trial comparisons
Solosec (Containing 2 Grams of Secnidazole) vs Placebo: serious adverse events	0 of 74	0 of 73	147	NCT03935217	Trial comparisons
Solosec 2 Grams vs Placebo: Microbiological Cure at the TOC Visit	59 of 64	1 of 67	131	NCT03935217	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21288838	RESULT	1	PubMed
42031495	DERIVED	1	PubMed
37550019	DERIVED	1	PubMed
33768237	DERIVED	1	PubMed
30297322	DERIVED	1	PubMed
21423852	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002154

GET https://conductscience.org/api/diseases/v1/MONDO_0002154/drugs

API reference For AI assistants